Sun Pharma will obtain 100% of Ranbaxy in an all stock transaction.

The collaboration of these two pharmaceutical companies leads to the fifth largest generics company globally. There will be operations in 65 countries as well as 47 manufacturing facilities across 5 continents.

Managing Director of Sun Pharma, Dilip Shanghvi said, “Ranbaxy has a significant presence in the Indian pharma market and in the US where it offers a broad portfolio of ANDAs and first-to-file opportunities. In high-growth emergingmarkets, it provides a strong platform which is highly complementary to SunPharma's strengths. We see tremendous growth opportunities and are excited with the prospects to create lasting value for both our shareholders through a successful combination of our franchises.”

Learn more about the companies at www.ranbaxy.com or www.sunpharma.com.